Year: 2023

CALGARY, Alberta, Nov. 13, 2023 (GLOBE NEWSWIRE) — In a release issued on November 9, 2023, the Adjusted EBITDA figure for the nine months ended September 30, 2023 in the reconciliation from net loss for the period to Adjusted EBITDA incorrectly had a bracket around the number. The brackets have been removed in this update. DIRTT Environmental Solutions Ltd. (“DIRTT” or the “Company”) (TSX: DRT; OTC: DRTTF), a leader in industrialized construction, today announced its financial results for the three and nine months ended September 30, 2023. All financial information in this news release is presented in U.S. dollars, unless otherwise stated.   Third Quarter 2023 HighlightsIn our seasonally strongest quarter, we generated revenue of $49.5 million, up 11% from the second quarter and 6% compared to the prior year period, and a net...

Cash and cash equivalents of approximately $11.5 million as of October 31, 2023 Special meeting of stockholders on November 16 seeking stockholder approval of the Dissolution and Plan of Dissolution If approved by stockholders, the Company estimates that cash distributions in the Dissolution will be between $5 million and $7 million, or $0.84 to $1.17 per share, to stockholders BOULDER, Colo., Nov. 13, 2023 (GLOBE NEWSWIRE) — Fresh Tracks Therapeutics, Inc. (the “Company” or “Fresh Tracks”) (Nasdaq: FRTX), today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update. “Following the approval by our Board of a plan of liquidation and dissolution of the Company, we have taken numerous actions over the last few weeks to reduce operating expenses and conserve capital, with the primary...

NEW YORK and TOKYO, Nov. 13, 2023 (GLOBE NEWSWIRE) — HeartCore Enterprises, Inc. (Nasdaq: HTCR) (“HeartCore” or “the Company”), a leading enterprise software and consulting services company based in Tokyo, reported financial results for the third quarter ended September 30, 2023. Third Quarter 2023 and Recent Operational HighlightsQ3 2023 Revenue of $4.7 million, 150% higher than Q3 2022. Enterprise software revenue doubled compared to Q3 2022. Consulting services revenues were only approximately $612,000, as client IPOs have been moved to Q4 2023. Year-to-Date 2023 revenue of $18.5 million, 172% higher than Q3 2022. Year-to-Date 2023 Net Loss of $1.8 million, or $(0.07) per share. Launched its digital experience platform, Daishiwake platform into the U.S. and Japanese markets. Awarded top market share (15%) in Japan for its...

SINGAPORE, Nov. 13, 2023 (GLOBE NEWSWIRE) — Bitdeer Technologies Group (NASDAQ: BTDR) (“Bitdeer” or the “Company”), a world-leading technology company for blockchain and high-performance computing, today announced its unaudited financial results for the third quarter ended September 30, 2023. Q3 2023 Financial HighlightsTotal revenue was US$87.3 million, compared to US$76.6 million in Q3 2022. Net loss was US$1.8 million, compared to a net loss of US$22.1 million in Q3 2022. Adjusted profit was US$10.5 million, compared to an adjusted loss of US$4.1 million in Q3 2022. Adjusted EBITDA was US$28.0 million, compared to US$8.7 million in Q3 2022. Cash and cash equivalents were US$134.5 million as of September 30, 2023.Linghui Kong, Chief Executive Officer of Bitdeer, commented, “We delivered another robust performance in the third...

– Announced topline results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the preventive treatment of episodic migraine that support advancing the program into a pivotal Phase 3 study – – Ongoing Phase 2 trial for the preventive treatment of chronic migraine has enrolled over 430 subjects; anticipate completing enrollment in Q4 2023 and announcing topline data in 2H 2024 – – Successfully completed business combination transaction and associated equity financings – IRVINE, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) — AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON, AEON WS), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, announced financial results for the third quarter ended September 30, 2023 and...

PLEASANTON, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) — Healthcare Triangle, Inc. (Nasdaq: HCTI) (“HCTI” or the “Company”), a leader in digital transformation solutions including managed services, cloud enablement, cybersecurity, data analytics, and AI data processing for the healthcare and life sciences industries, today announced results for the third quarter of 2023 ended September 30, 2023. Thyagarajan Ramachandran, CFO of Healthcare Triangle, said, “A return to predictable revenue growth is top priority for the current quarter and throughout 2024. During the third quarter we launched an exciting new initiative working with U.S. health systems on an HCTI-branded ransomware protection framework and methodology. The response so far has been encouraging, and our goal is to become a top provider of robust cybersecurity services...

Completed enrollment of 380 patients in pivotal Phase 3 trial of lead therapeutic cancer vaccine, IO102-IO103 in combination with KEYTRUDA® (pembrolizumab), in patients with advanced melanoma Presented encouraging preliminary data from Phase 2 basket trial of IO102-IO103 at the IASLC 2023 World Conference on Lung Cancer (WCLC) in September 2023 and at the European Society of Medical Oncology (ESMO) annual meeting in October 2023 Presented three posters at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting; non-clinical data presented demonstrates clear impact of immune modulating vaccines targeting IDO1 and PD-L1 on several tumoral immune escape mechanisms in the tumor microenvironment leading to enhanced anti-tumor effect Ended the third quarter with approximately $165.5 million in cash and cash equivalents, including...